Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 (2021)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1056/NEJMoa2103417
- Subjects: COVID-19; TROMBOSE; ANTICOAGULANTES
- Agências de fomento:
- European Union through FP7-HEALTH-2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium
- Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium
- Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia
- Health Research Council of New ZealandHealth Research Council of New Zealand
- Canadian Institutes of Health Research (Strategy for Patient-Oriented Research Innovative Clinical Trials Program)Canadian Institutes of Health Research (CIHR)
- COVID-19 Rapid Research Operating Grant
- U.K. National Institute for Health Research (NIHR)National Institute for Health Research (NIHR)
- NIHR Imperial Biomedical Research Centre
- Health Research Board of Ireland [CTN]
- Translational Breast Cancer Research Consortium
- French Ministry of Health [PHRC]
- Minderoo Foundation
- AmgenAmgen
- Global Coalition for Adaptive Research
- Wellcome TrustWellcome TrustEuropean Commission
- Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)
- CancerCare Manitoba Foundation, Victoria General Hospital Foundation
- Ontario Ministry of HealthMinistry of Health and Long-Term Care, Ontario
- Peter Munk Cardiac CentreUniversity of Toronto
- National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [OTA-20-011]
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: New england journal of medicine
- ISSN: 0028-4793
- Volume/Número/Paginação/Ano: v. 385, n. 9, p. 777-789, 2021
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
GOLIGHER, Ewan C et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New england journal of medicine, v. 385, n. 9, p. 777-789, 2021Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa2103417. Acesso em: 05 jun. 2024. -
APA
Goligher, E. C., Bradbury, C. A., Mcverry, B. J., Lawler, P. R., Berger, J. S., Gong, M. N., et al. (2021). Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New england journal of medicine, 385( 9), 777-789. doi:10.1056/NEJMoa2103417 -
NLM
Goligher EC, Bradbury CA, Mcverry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Nicolau JC. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 777-789.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1056/NEJMoa2103417 -
Vancouver
Goligher EC, Bradbury CA, Mcverry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Nicolau JC. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 777-789.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1056/NEJMoa2103417 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1056/NEJMoa2103417 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
